Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Subjects With Multiple Myeloma

Next Previous
Trial Profile

A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Subjects With Multiple Myeloma

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daratumumab (Primary) ; Pomalidomide (Primary) ; Talquetamab (Primary) ; Talquetamab (Primary) ; Teclistamab (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; First in man
  • Acronyms TRIMM-2
  • Sponsors Janssen Research & Development; Janssen-Cilag

Most Recent Events

  • 10 Feb 2026 According to a Johnson & Johnson media release, announced that it has applied for approval for a partial change in the manufacturing and marketing approval of Techvei hereinafter referred to as Techvai for the treatment of relapsed or refractory multiple myeloma with the anti-CD38 monoclonal antibody formulation Daraculo and subcutaneous injection generic name: daratumumab.
  • 10 Oct 2025 Planned primary completion date changed from 22 Aug 2025 to 7 Apr 2027.
  • 03 Feb 2025 Planned End Date changed from 22 Aug 2025 to 7 Apr 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top